SDB-005 (also known as NA-PINAC using systematic EUDA nomenclature) is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-005 is the indazole core analog of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.
The code number SDB-005 was originally used by Samuel D. Bannister for a different compound, the N-phenyl instead of N-benzyl analogue of SDB-006, pictured. It is systematically named PH-PICA (Phen-1-yl 1-Pentyl-1H-indazole-3-carboxamide. This compound is a potent agonist of the CB1 receptor (Ki = 21 nM) and CB2 receptor (Ki = 140 nM) but has significant chemical differences; an indazole ring (instead of indole ring), a carboxamide linker (instead of carboxylate ester) and linked phenyl (instead of naphtyl) group).
However, SDB-005 was subsequently used as the name for the indazole-3-napthyl-carboxylate compound when it was sold in Europe as a designer drug. Because of this, it was entered into the EMCDDA synthetic drug database under this name.EWS_EU: Neue Psychoaktive Substanzen, April 2015 The UK Forensic Early Warning System reported a detection of SDB-005 in December 2017 as the first occurrence of naphthalen-1-yl-1-pentyl-1H-indazole-3-carboxylate (NA-PINAC) in the UK. Many online sources now list SDB-005 as naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate (NA-PINAC).
Consequently, there are now two distinct, yet fairly closely related cannabinoid compounds, which may both be referred to under the code SDB-005.
See also 5F-PB-22 AM-2201 BB-22 JWH-018 NM-2201 NNE1
References